CHINET 2007 Surveillance of Antibiotic Resistance in Enterobacter Spp in China

李丽,童先丽,田磊,张蓓,简翠,孙自镛,徐英春,孙宏莉,俞云松,杨青,张泓,李万华,胡云健,艾效曼,倪语星,孙景勇,魏莲花,吴玲,汪复,朱德妹,胡付品,阮斐怡,贾蓓,黄文祥,王传清,薛建昌,卓超,苏丹虹,张朝霞,季萍
DOI: https://doi.org/10.3321/j.issn:1009-7708.2009.03.008
2009-01-01
Abstract:Objective To investigate the distribution and antibiotic resistance clinical Enterobacter isolates.Methods A total of 1 231 clinical strains of Enterobacter spp were collected from 12 hospitals during January 1 through December 31, 2007. Antimicrobial susceptibility testing was performed with Kirby-Bauer method. The results were analyzed according to CLSI 2007 standards.Results The main source of Enterobacter was sputum (60.5%, 745/1 231) and urine (11.9%, 147/1 231), blood (5.4%, 66/1 231), and cerebrospinal fluid (0.9%, 11/1 231) followed by aseptic body fluid (3.2%, 39/1 231). The resistance rate (93.0%) to cefoxitin was the highest. The rate of resistance to cefotaxime, and ceftazidime, was relatively higher (36.9% to 37.7%). However, the rate of resistance to cefepime, amikacin, gentamicin and ciprofloxacin was relatively lower (13.7% to 28.0%). The rate of resistance to imipenem and meropenem was the lowest (0.9%).Conclusions Antibiotic resistance of Enterobacter spp is serious in China. Especially, carbapenems-resistant Enterobacter isolates were identified. Every hospital should take effective control measures to curb the growth of resistant strains.
What problem does this paper attempt to address?